Daunorubicin-prednisone remission induction with hydroxyurea maintenance in acute non-lymphocytic leukemia.
D000328:Adult; D000367:Age Factors; D003630:Daunorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use*; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy* / Q000401:mortality; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008213:Lymphocyte Activation; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D012737:Sex Factors
D011241:Prednisone; D006918:Hydroxyurea; D003630:Daunorubicin